How are energy investors positioned?
IRVING, TX—Rutledge Napoleon B Jr, the Senior Vice President, Controller, and Chief Accounting Officer at McKesson Corp (NYSE:MCK), recently sold shares of the company’s common stock. According to a filing with the Securities and Exchange Commission, Napoleon sold 95 shares on May 28, 2025, at a price of $717.91 per share. The transaction totaled $68,201.
This sale was conducted under a pre-established trading plan, in compliance with Rule 10b5-1(c), which allows insiders to set up a trading plan for selling stocks they own. After the transaction, Napoleon continues to hold 986 shares of McKesson stock directly. According to InvestingPro analysis, McKesson maintains a GREAT financial health score, with notably strong price momentum and profitability metrics.
McKesson Corp, a major player in the healthcare supply chain, remains a focal point for investors watching insider transactions for potential insights into the company’s future performance.
In other recent news, McKesson Corporation has reported a robust fiscal fourth quarter, surpassing Wall Street’s earnings expectations by 3%. The company announced an earnings per share (EPS) that exceeded consensus estimates and provided an optimistic EPS guidance for fiscal year 2026, which is above current market expectations. McKesson’s management has maintained a long-term EPS growth outlook of 12% to 14% and increased its operating income growth projection for its core U.S. Pharmaceutical (TADAWUL:2070) segment to between 6% and 8%.
Jefferies analyst Rob Dickerson responded to these developments by raising the price target for McKesson shares to $800 from $715, while maintaining a Buy rating. In the third quarter of 2025, McKesson reported adjusted EPS of $10.12, beating the forecast, although revenue fell short of expectations at $90.82 billion against a $93.48 billion forecast. Despite the revenue miss, McKesson’s strategic acquisitions in healthcare services and cost optimization efforts have bolstered growth and resulted in $100 million in savings.
Looking forward, McKesson has issued a revenue growth guidance of 11% to 15% for fiscal 2026, with an anticipated EPS range of $36.05 to $37.55. The company plans to separate its Medical (TASE:BLWV) Surgical segment into an independent entity, aiming to enhance focus and operational efficiency. These strategic moves underscore McKesson’s commitment to maintaining a strong financial position and addressing key investor concerns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.